An Open-Label, Two-Single Dose, Two-Period, Parallel Group Study to Assess the Pharmacokinetics and Safety of ALXN1840 in Healthy Adult Japanese and Non-Japanese Subjects
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Tiomolibdate choline (Primary)
- Indications Hepatolenticular degeneration
- Focus Pharmacokinetics
- Sponsors Alexion AstraZeneca Rare Disease
- 29 Nov 2022 Status changed from recruiting to completed.
- 16 Apr 2014 Status changed from not yet recruiting to recruiting, as reported in a Wilson Therapeutics media release.
- 17 Jan 2014 New trial record